Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2003 Feb;74(2):170–174. doi: 10.1136/jnnp.74.2.170

Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson's disease patients previously reliant on apomorphine

T Varma 1, S Fox 1, P Eldridge 1, P Littlechild 1, P Byrne 1, A Forster 1, A Marshall 1, H Cameron 1, K McIver 1, N Fletcher 1, M Steiger 1
PMCID: PMC1738303  PMID: 12531942

Abstract

Objectives: To assess the efficacy of bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) in patients with advanced Parkinson's disease previously reliant on apomorphine as their main antiparkinsonian medication.

Methods: Seven patients with motor fluctuations despite optimal medical treatment given as predominantly apomorphine infusion (n=6), or intermittent apomorphine injections (n=1) underwent bilateral STN DBS using frameless stereotactic surgery. Standard assessments of parkinsonism and motor fluctuations, using Unified Parkinson's Disease Rating Scale (UPDRS) were performed before and six months after surgery. Assessments were performed both on and off medication, and postoperative with the stimulators switched on and off.

Results: Bilateral STN DBS improved motor scores (UPDRS III) by 61% when off medication (p<0.05). Clinical fluctuations (UPDRS IV items 36–39) were reduced by 46.2% (p<0.05). Total daily apomorphine dose was reduced by 68.9% (p<0.05) and apomorphine infusion via a pump was no longer required in four patients. There were no operative complications. Two patients required treatment for hallucinations postoperatively but there was no significant change in mini-mental state examination.

Conclusions: In patients with advanced Parkinson's disease, previously reliant on apomorphine, bilateral STN DBS is an effective treatment to reduce motor fluctuations and enable a reduction in apomorphine use.

Full Text

The Full Text of this article is available as a PDF (109.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bejjani B. P., Arnulf I., Demeret S., Damier P., Bonnet A. M., Houeto J. L., Agid Y. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible? Ann Neurol. 2000 May;47(5):655–658. [PubMed] [Google Scholar]
  2. Fraix V., Pollak P., Van Blercom N., Xie J., Krack P., Koudsie A., Benabid A. L. Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease. Neurology. 2000 Dec 26;55(12):1921–1923. doi: 10.1212/wnl.55.12.1921. [DOI] [PubMed] [Google Scholar]
  3. Frankel J. P., Lees A. J., Kempster P. A., Stern G. M. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990 Feb;53(2):96–101. doi: 10.1136/jnnp.53.2.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hagell P., Widner H. Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale. Mov Disord. 1999 May;14(3):448–455. doi: 10.1002/1531-8257(199905)14:3<448::aid-mds1010>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  5. Hassani O. K., Féger J. Effects of intrasubthalamic injection of dopamine receptor agonists on subthalamic neurons in normal and 6-hydroxydopamine-lesioned rats: an electrophysiological and c-Fos study. Neuroscience. 1999;92(2):533–543. doi: 10.1016/s0306-4522(98)00765-9. [DOI] [PubMed] [Google Scholar]
  6. Hughes A. J., Daniel S. E., Kilford L., Lees A. J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181–184. doi: 10.1136/jnnp.55.3.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kreiss D. S., Mastropietro C. W., Rawji S. S., Walters J. R. The response of subthalamic nucleus neurons to dopamine receptor stimulation in a rodent model of Parkinson's disease. J Neurosci. 1997 Sep 1;17(17):6807–6819. doi: 10.1523/JNEUROSCI.17-17-06807.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kumar R., Lozano A. M., Kim Y. J., Hutchison W. D., Sime E., Halket E., Lang A. E. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology. 1998 Sep;51(3):850–855. doi: 10.1212/wnl.51.3.850. [DOI] [PubMed] [Google Scholar]
  9. Limousin P., Krack P., Pollak P., Benazzouz A., Ardouin C., Hoffmann D., Benabid A. L. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 1998 Oct 15;339(16):1105–1111. doi: 10.1056/NEJM199810153391603. [DOI] [PubMed] [Google Scholar]
  10. Lozano A. M., Lang A. E., Galvez-Jimenez N., Miyasaki J., Duff J., Hutchinson W. D., Dostrovsky J. O. Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet. 1995 Nov 25;346(8987):1383–1387. doi: 10.1016/s0140-6736(95)92404-3. [DOI] [PubMed] [Google Scholar]
  11. Mitchell I. J., Clarke C. E., Boyce S., Robertson R. G., Peggs D., Sambrook M. A., Crossman A. R. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience. 1989;32(1):213–226. doi: 10.1016/0306-4522(89)90120-6. [DOI] [PubMed] [Google Scholar]
  12. Molinuevo J. L., Valldeoriola F., Tolosa E., Rumia J., Valls-Sole J., Roldan H., Ferrer E. Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease. Arch Neurol. 2000 Jul;57(7):983–988. doi: 10.1001/archneur.57.7.983. [DOI] [PubMed] [Google Scholar]
  13. Moro E., Scerrati M., Romito L. M., Roselli R., Tonali P., Albanese A. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology. 1999 Jul 13;53(1):85–90. doi: 10.1212/wnl.53.1.85. [DOI] [PubMed] [Google Scholar]
  14. Nutt J. G. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology. 1990 Feb;40(2):340–345. doi: 10.1212/wnl.40.2.340. [DOI] [PubMed] [Google Scholar]
  15. Obeso J. A., Grandas F., Vaamonde J., Rosario Luguin M., Martínez-Lage J. M. Apomorphine infusion for motor fluctuations in Parkinson's disease. Lancet. 1987 Jun 13;1(8546):1376–1377. doi: 10.1016/s0140-6736(87)90679-9. [DOI] [PubMed] [Google Scholar]
  16. Obeso J. A., Rodriguez-Oroz M. C., Rodriguez M., Macias R., Alvarez L., Guridi J., Vitek J., DeLong M. R. Pathophysiologic basis of surgery for Parkinson's disease. Neurology. 2000;55(12 Suppl 6):S7–12. [PubMed] [Google Scholar]
  17. Pierantozzi M., Palmieri M. G., Mazzone P., Marciani M. G., Rossini P. M., Stefani A., Giacomini P., Peppe A., Stanzione P. Deep brain stimulation of both subthalamic nucleus and internal globus pallidus restores intracortical inhibition in Parkinson's disease paralleling apomorphine effects: a paired magnetic stimulation study. Clin Neurophysiol. 2002 Jan;113(1):108–113. doi: 10.1016/s1388-2457(01)00694-0. [DOI] [PubMed] [Google Scholar]
  18. Saint-Cyr J. A., Trépanier L. L., Kumar R., Lozano A. M., Lang A. E. Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. Brain. 2000 Oct;123(Pt 10):2091–2108. doi: 10.1093/brain/123.10.2091. [DOI] [PubMed] [Google Scholar]
  19. Stibe C. M., Lees A. J., Kempster P. A., Stern G. M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet. 1988 Feb 20;1(8582):403–406. doi: 10.1016/s0140-6736(88)91193-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES